Drugmakers vie for Trump’s attention in race to find a coronavirus cure

2 min


77
12 shares, 77 points
Drugmakers vie for Trump’s attention in race to find a coronavirus cure 1

The industry moves also come amid a backdrop of renewed drug pricing talks in Congress, where lawmakers are readying their wish lists for a fourth coronavirus relief package. Democrats and Republicans alike have said that the possibility of coronavirus cures and vaccines within the year necessitates new drug pricing measures.

Pharmaceutical companies developing coronavirus cures and vaccines are looking to change that conversation and emphasize the life-changing products they could bring to the table. The industry has been on the defensive for years on drug pricing, generic competition and market exclusivity; the president himself said days before assuming office that the companies were “getting away with murder.”

“This allows them to remind customers, or potential customers, and elected officials why they exist and the benefits they can bring,” Heye said. “It’s not just a different conversation in topic, it’s a different conversation in tone. It moved from an almost universally negative conversation to a positive one.”

Johnson & Johnson, which is aiming for an emergency authorization for its potential vaccine in early 2021, said this week that it plans to offer the booster on a “not-for-profit” basis. The company’s web series aims to demystify the vaccine development for consumers, said Seema Kumar, J&J’s global leader for innovation, health and scientific communications, who has spearheaded the J&J show.

“People are so hungry for information. One of the things that science, and progress in science, provides is hope,” said Kumar. “Whenever our chief science officer talks about the vaccine, people go away feeling like somebody is working on something that is going to be helping everybody.”

The company’s second episode will answer viewer questions and there are talks to expand with partnerships for the show in countries like India. More than 50,000 people worldwide tuned into the first livestream and it later racked up 80,000 views on LinkedIn.

Others are more cynical about the effort. NYU’s Morten argued that the first J&J episode focuses on the company effort without acknowledging hundreds of millions of dollars poured in from the government at this point.

“A TV show that takes the American public around the sparkling, shiny, fancy-looking science labs at J&J is the perfect foundation for a fight six months from now over the prices that J&J is targeting,” said Morten.


Like it? Share with your friends!

77
12 shares, 77 points

What's Your Reaction?

hate hate
10
hate
confused confused
2
confused
fail fail
16
fail
fun fun
14
fun
geeky geeky
12
geeky
love love
6
love
lol lol
8
lol
omg omg
2
omg
win win
16
win

Read exclusive latest news on entertainment, music, gaming and more topics with unprecedented coverage from around the UK and US.

0 Comments

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.